Cargando…
Optimising pharmacotherapy in older cancer patients with polypharmacy
OBJECTIVE: Polypharmacy is frequent among older cancer patients and increases the risk of potential drug‐related problems (DRPs). DRPs are associated with adverse drug events, drug‐drug interactions and hospitalisations. Since no standardised polypharmacy assessment methods for oncology patients exi...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7063689/ https://www.ncbi.nlm.nih.gov/pubmed/31692151 http://dx.doi.org/10.1111/ecc.13185 |
_version_ | 1783504738227060736 |
---|---|
author | Vrijkorte, Elze de Vries, Jennifer Schaafsma, Ron Wymenga, Machteld Oude Munnink, Thijs |
author_facet | Vrijkorte, Elze de Vries, Jennifer Schaafsma, Ron Wymenga, Machteld Oude Munnink, Thijs |
author_sort | Vrijkorte, Elze |
collection | PubMed |
description | OBJECTIVE: Polypharmacy is frequent among older cancer patients and increases the risk of potential drug‐related problems (DRPs). DRPs are associated with adverse drug events, drug‐drug interactions and hospitalisations. Since no standardised polypharmacy assessment methods for oncology patients exist, we aimed to develop one that can be integrated into routine care. METHODS: Based on the Systematic Tool to Reduce Inappropriate Prescribing (STRIP), we developed OncoSTRIP, which includes a polypharmacy anamnesis, a concise geriatric assessment, a polypharmacy analysis taking life expectancy into account and an optimised treatment plan. Patients ≥65 years with ≥5 chronic drugs visiting our outpatient oncology clinic were eligible for the polypharmacy assessment. RESULTS: OncoSTRIP was integrated into routine care of our older cancer patients. In 47 of 60 patients (78%), potential DRPs (n = 101) were found. In total, 85 optimisations were recommended, with an acceptance rate of 41%. It was possible to reduce the number of potential DRPs by 41% and the number of patients with at least one potential DRP by 30%. Mean time spent per patient was 71 min. CONCLUSIONS: Polypharmacy assessment of older cancer patients identifies many pharmacotherapeutic optimisations. With OncoSTRIP, polypharmacy assessments can be integrated into routine care. |
format | Online Article Text |
id | pubmed-7063689 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-70636892020-03-16 Optimising pharmacotherapy in older cancer patients with polypharmacy Vrijkorte, Elze de Vries, Jennifer Schaafsma, Ron Wymenga, Machteld Oude Munnink, Thijs Eur J Cancer Care (Engl) Original Articles OBJECTIVE: Polypharmacy is frequent among older cancer patients and increases the risk of potential drug‐related problems (DRPs). DRPs are associated with adverse drug events, drug‐drug interactions and hospitalisations. Since no standardised polypharmacy assessment methods for oncology patients exist, we aimed to develop one that can be integrated into routine care. METHODS: Based on the Systematic Tool to Reduce Inappropriate Prescribing (STRIP), we developed OncoSTRIP, which includes a polypharmacy anamnesis, a concise geriatric assessment, a polypharmacy analysis taking life expectancy into account and an optimised treatment plan. Patients ≥65 years with ≥5 chronic drugs visiting our outpatient oncology clinic were eligible for the polypharmacy assessment. RESULTS: OncoSTRIP was integrated into routine care of our older cancer patients. In 47 of 60 patients (78%), potential DRPs (n = 101) were found. In total, 85 optimisations were recommended, with an acceptance rate of 41%. It was possible to reduce the number of potential DRPs by 41% and the number of patients with at least one potential DRP by 30%. Mean time spent per patient was 71 min. CONCLUSIONS: Polypharmacy assessment of older cancer patients identifies many pharmacotherapeutic optimisations. With OncoSTRIP, polypharmacy assessments can be integrated into routine care. John Wiley and Sons Inc. 2019-11-06 2020-01 /pmc/articles/PMC7063689/ /pubmed/31692151 http://dx.doi.org/10.1111/ecc.13185 Text en © 2019 The Authors. European Journal of Cancer Care published by John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Vrijkorte, Elze de Vries, Jennifer Schaafsma, Ron Wymenga, Machteld Oude Munnink, Thijs Optimising pharmacotherapy in older cancer patients with polypharmacy |
title | Optimising pharmacotherapy in older cancer patients with polypharmacy |
title_full | Optimising pharmacotherapy in older cancer patients with polypharmacy |
title_fullStr | Optimising pharmacotherapy in older cancer patients with polypharmacy |
title_full_unstemmed | Optimising pharmacotherapy in older cancer patients with polypharmacy |
title_short | Optimising pharmacotherapy in older cancer patients with polypharmacy |
title_sort | optimising pharmacotherapy in older cancer patients with polypharmacy |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7063689/ https://www.ncbi.nlm.nih.gov/pubmed/31692151 http://dx.doi.org/10.1111/ecc.13185 |
work_keys_str_mv | AT vrijkorteelze optimisingpharmacotherapyinoldercancerpatientswithpolypharmacy AT devriesjennifer optimisingpharmacotherapyinoldercancerpatientswithpolypharmacy AT schaafsmaron optimisingpharmacotherapyinoldercancerpatientswithpolypharmacy AT wymengamachteld optimisingpharmacotherapyinoldercancerpatientswithpolypharmacy AT oudemunninkthijs optimisingpharmacotherapyinoldercancerpatientswithpolypharmacy |